A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers
Latest Information Update: 14 Apr 2022
Price :
$35 *
At a glance
- Drugs CSTC 1 (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Sponsors Charsire Biotechnology Corporation
- 16 Jul 2020 Status changed from recruiting to completed.
- 29 Jul 2019 Planned End Date changed from 1 Sep 2019 to 1 Jun 2020.
- 29 Jul 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2020.